BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 7873457)

  • 1. Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer.
    Pérez Carrión R; Alberola Candel V; Calabresi F; Michel RT; Santos R; Delozier T; Goss P; Mauriac L; Feuilhade F; Freue M
    Ann Oncol; 1994; 5 Suppl 7():S19-24. PubMed ID: 7873457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Formestane: effective therapy in postmenopausal women with advanced breast cancer.
    Bajetta E; Zilembo N; Buzzoni R; Noberasco C; Martinetti A; Ferrari L; Bartoli C; Sacchini V; Attili A; Lepera P
    Ann Oncol; 1994; 5 Suppl 7():S15-7. PubMed ID: 7873456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of advanced breast cancer with formestane.
    Murray R; Pitt P
    Ann Oncol; 1994; 5 Suppl 7():S11-3. PubMed ID: 7873455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Formestane. A review of its pharmacological properties and clinical efficacy in the treatment of postmenopausal breast cancer.
    Wiseman LR; Goa KL
    Drugs Aging; 1996 Oct; 9(4):292-306. PubMed ID: 8894526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Formestane in the treatment of advanced postmenopausal breast cancer.
    Possinger K; Jonat W; Höffken K
    Ann Oncol; 1994; 5 Suppl 7():S7-10. PubMed ID: 7873464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: a phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90). Swiss Group for Clinical Cancer Research (SAKK).
    Thürlimann B; Castiglione M; Hsu-Schmitz SF; Cavalli F; Bonnefoi H; Fey MF; Morant R; Löhnert T; Goldhirsch A
    Eur J Cancer; 1997 Jun; 33(7):1017-24. PubMed ID: 9376181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen.
    Goss PE; Clark RM; Ambus U; Weizel HA; Wadden NA; Crump M; Walde D; Tye LM; De Coster R; Bruynseels J
    Clin Cancer Res; 1995 Mar; 1(3):287-94. PubMed ID: 9815984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proper sequence of endocrine therapies in advanced breast cancer.
    Rose C
    Acta Oncol; 1996; 35 Suppl 5():44-9. PubMed ID: 9142964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of formestane in de novo tamoxifen-resistant patients with metastatic breast cancer.
    Noberasco C; Bajetta E; Zilembo N; Di Leo A; Cappuzzo F; Bartoli C; Bono A; Bichisao E
    Oncology; 1995; 52(6):454-7. PubMed ID: 7478430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95--a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and Tolerability) trial.
    Thürlimann B; Hess D; Köberle D; Senn I; Ballabeni P; Pagani O; Perey L; Aebi S; Rochlitz C; Goldhirsch A
    Breast Cancer Res Treat; 2004 Jun; 85(3):247-54. PubMed ID: 15111763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Formestane. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of breast cancer and prostatic cancer.
    Wiseman LR; McTavish D
    Drugs; 1993 Jan; 45(1):66-84. PubMed ID: 7680986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Formestane is feasible and effective in elderly breast cancer patients with comorbidity and disability.
    Venturino A; Comandini D; Granetto C; Audisio RA; Castiglione F; Ross R; Repetto L
    Breast Cancer Res Treat; 2000 Aug; 62(3):217-22. PubMed ID: 11072786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Formestane: an effective first-line endocrine treatment for advanced breast cancer.
    Zilembo N; Bajetta E; Noberasco C; Buzzoni R; Vicario G; Bono A; Laffranchi A; Biasi G; Dolci S; Bichisao E
    J Cancer Res Clin Oncol; 1995; 121(6):378-82. PubMed ID: 7797604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pilot study of formestane in postmenopausal women with breast cancer.
    Joseph JK; Lim AK
    Med J Malaysia; 1998 Mar; 53(1):37-41. PubMed ID: 10968135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer.
    Cohen MH; Johnson JR; Li N; Chen G; Pazdur R
    Clin Cancer Res; 2002 Mar; 8(3):665-9. PubMed ID: 11895893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicentre, randomized, pharmacokinetic, endocrine and clinical study to evaluate formestane in breast cancer patients at first relapse: endocrine and clinical results. The Italian Trials in Medical Oncology (I.T.M.O.) group.
    Bajetta E; Zilembo N; Barni S; Noberasco C; Martinetti A; Ferrari L; Schieppati G; Buzzoni R; Jirillo A; Amichetti M; D'Aprile M; Comella G; Bichisao E; Bolelli GF; Attili A; Bombardieri E
    Ann Oncol; 1997 Jul; 8(7):649-54. PubMed ID: 9296217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anastrozole shows evidence of activity in postmenopausal patients who have responded or stabilised on formestane therapy.
    Harper-Wynne C; Coombes RC
    Eur J Cancer; 1999 May; 35(5):744-6. PubMed ID: 10505035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
    ; Thürlimann B; Keshaviah A; Coates AS; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Rabaglio M; Smith I; Wardley A; Price KN; Goldhirsch A
    N Engl J Med; 2005 Dec; 353(26):2747-57. PubMed ID: 16382061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
    Goss PE; Ingle JN; Martino S; Robert NJ; Muss HB; Piccart MJ; Castiglione M; Tu D; Shepherd LE; Pritchard KI; Livingston RB; Davidson NE; Norton L; Perez EA; Abrams JS; Therasse P; Palmer MJ; Pater JL
    N Engl J Med; 2003 Nov; 349(19):1793-802. PubMed ID: 14551341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis.
    Mauri D; Pavlidis N; Polyzos NP; Ioannidis JP
    J Natl Cancer Inst; 2006 Sep; 98(18):1285-91. PubMed ID: 16985247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.